Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
U.S. Department of Health and Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD 036071)
U.S. Department of Health and Human Services | NIH | National Institute of Neurological Disorders and Stroke (NS 128751)
MIND Institute, University of California, Davis (P50 HD103526)
- License Information
-
More Information
Article History
Received: 4 May 2022
Accepted: 1 December 2022
First Online: 10 December 2022
Competing interests
: The funders (NICHD, NINDS) had no role in the study’s design, in the collection, analysis, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results. R.J.H. has received funding from Zynerba and the Azrieli Foundation for carrying out treatment studies in patients with fragile X syndrome. She has also consulted with Zynerba regarding treatment studies in individuals with FXS. C.G. is an Editorial Board Member of <i>Scientific Reports</i> and received compensation as a Specialty Chief Editor for <i>Frontiers in Cell and Developmental Biology</i>. R.J.H. and C.G. received honoraria from participating in NIH peer review meetings. J.Y.W. has no conflict to declare. No other potential financial and non-financial competing interests that could directly or indirectly undermine the objectivity, integrity, and value of this publication through a potential influence on the judgments and actions of authors regarding objective data presentation, analysis, and interpretation, are found.
